“Internationally renowned Industry veteran Steve Bagshaw joins Arcinova board to propel continued industry-leading growth”
Arcinova, one of the fastest-growing multi-service Contract Development and Manufacturing Organisations (CDMOs), is delighted to welcome Steve Bagshaw to its board as a Non-Executive Director. Steve has almost two decades of board-level experience, including leadership roles within Japanese, American and UK Private Equity corporate cultures. His proven acumen drove the rapid growth of a CDMO from $50m to over $600m turnover including transformational acquisitions both in Europe and the US.
Steve’s appointment continues Arcinova’s strategy of strengthening the company board following the appointment of Roger Kilburn as CEO in 2019. Steve’s contribution will be pivotal to the continued growth of the business over the next few years, underpinned by the company’s investor, Business Growth Fund (BGF), who are fully supportive of our continued development.
With its board now complete, Arcinova looks to the future with renewed optimism and confidence. In line with the company’s growth strategy, Arcinova will look to make strategic acquisitions as appropriate to further enhance the scope and accessibility of its offerings to its international customer base.
Steve Bagshaw commented, “I am delighted to be joining the team at Arcinova as a Non-Executive Director. The Leadership Team have already established an impressive track record and I have every confidence they will continue to grow the business rapidly. I am looking forward to working with them on this journey of growth.”
Ian Shott, Executive Chairman at Arcinova, commented, “We are enormously privileged to welcome Steve to our board. His unparalleled experience will be invaluable to us as we continue the already remarkable journey of Arcinova.”
Arcinova is a Contract Development and Manufacturing Organisation that helps pharmaceutical and biotechnology companies across the globe develop life-changing medicines. We employ a multidisciplinary approach to drug development by combining chemistry, biology and bioinformatics. All our services are delivered from our 15,000m2 facility in the North East of England.
We leverage our decades of experience as a key research and development centre to deliver high quality end-to-end solutions. Our mission is to deliver best-in-class technology services in the fields of contract research, development and small-scale manufacturing to overcome project challenges and increase efficiency.
For more information, visit www.arcinova.com